Press releases Nektar in the news Items Per Page 102550 News Category AllFinancialGeneral Year All202620252024202320222021202020192018201720162015201420132012201120102009200820072006 Jun 03, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York May 07, 2026 Nektar Therapeutics Reports First Quarter 2026 Financial Results May 01, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 28, 2026 Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets Apr 23, 2026 Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares Apr 21, 2026 Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering Apr 20, 2026 Nektar Therapeutics Announces Proposed Public Offering Apr 20, 2026 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin Apr 19, 2026 Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 Contact IR Print Page RSS Email Alerts
Nektar in the news Items Per Page 102550 News Category AllFinancialGeneral Year All202620252024202320222021202020192018201720162015201420132012201120102009200820072006 Jun 03, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York May 07, 2026 Nektar Therapeutics Reports First Quarter 2026 Financial Results May 01, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 28, 2026 Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets Apr 23, 2026 Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares Apr 21, 2026 Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering Apr 20, 2026 Nektar Therapeutics Announces Proposed Public Offering Apr 20, 2026 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin Apr 19, 2026 Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Apr 28, 2026 Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
Apr 23, 2026 Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Apr 20, 2026 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
Apr 19, 2026 Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
